SAN ANTONIO–(BUSINESS WIRE)–Acelity L.P. Inc. (“Acelity”), a global advanced wound care and regenerative medicine company, announced today the pricing of the private offering by its wholly-owned subsidiaries, Kinetic Concepts, Inc. (“KCI”) and KCI USA, Inc. (together with KCI, the “Issuers”), of $1,750.0 million in aggregate principal amount of 9.625% second lien senior secured notes due 2021 (the “Notes”).

The Issuers intend to use the gross proceeds from the Notes offering, together with proceeds of a $100.0 million equity contribution by Acelity’s sponsors (the “Equity Contribution”) and cash on hand (including borrowings under the Issuers’ revolving credit facility), to redeem $1,750.0 million in aggregate principal amount of their outstanding 10.5% second lien senior secured notes due 2018 and to pay the fees and expenses related to such offering, redemption, the Equity Contribution and other financing transactions. The consummation of the Notes offering is conditioned upon the substantially concurrent consummation of the Equity Contribution.

The Notes offering is expected to close on September 20, 2016, subject to customary closing conditions.

The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), only to “qualified institutional buyers” in accordance with Rule 144A under the Securities Act and to non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act.

This press release does not and will not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Notes and the related note guarantees have not and will not be registered under the Securities Act or any state securities laws, and may not be offered or sold in the United States to, or for the benefit of, U.S. persons except pursuant to an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

Forward-Looking Statements

Certain statements included in this press release may be considered “forward-looking statements”, which are based on information available to Acelity on the date of this release. Words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” the negative versions of these words and/or similar terms and phrases are used to identify these forward looking statements. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties. Acelity cannot assure you that future developments affecting Acelity will be those that have been anticipated. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market regulatory and other factors, many of which are beyond Acelity’s control, as well as other risks described from time to time under “Risk Factors” in Acelity’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q (available at www.sec.gov). Any forward-looking statement speaks only as of the date of this press release. Factors or events that could cause Acelity’s actual results to differ may emerge from time to time, and it is not possible to predict all of them. Acelity may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. Acelity’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions Acelity may make. Acelity undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

PARIS–(BUSINESS WIRE)–EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced the sale of an EOS system to the Carolinas HealthCare System. The system will be located at a dedicated imaging center in Carolina HealthCare’s Morehead Medical Plaza campus in Charlotte, NC. It will be available for pediatric and adult patients in the Carolinas HealthCare System, including those served at the Levine Children’s Hospital, which is also located in the Morehead Medical Plaza. The Levine Children’s Hospital was named a Best Children’s Hospital by U.S. News & World Report in orthopedics¹.

Carolinas HealthCare System is one of the leading healthcare organizations in the Southeast and one of the most comprehensive systems in the country. The organization includes more than 900 care locations and 7,500 beds throughout North and South Carolina.

Marie Meynadier, CEO of EOS imaging, said, “We are pleased that the unique benefits of the EOS system and services will soon be available to patients in the North and South Carolina area. Adoption by such a prestigious group further validates our technology. In addition, this sale marks the entry into another large hospital network in the U.S., which further expands patient access to the EOS technology and provides incremental growth potential within the hospital network.”

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

About EOS imaging

EOS imaging designs, develops, and markets EOS^®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States, Japan, China, and the European Union. The Group posted 2015 revenues of €21.8 million and employs 122 people. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

¹ http://www.carolinashealthcare.org/about-us

NEW YORK–(BUSINESS WIRE)–Empire BlueCross BlueShield has been selected as a payer participant in the Centers for Medicare & Medicaid Services’ Comprehensive Primary Care Plus (CPC+) initiative, a five-year multi-payer model that’s the largest federal investment in primary care transformation to date.

“Empire’s involvement in CPC+ reflects our belief in the important role that the primary care doctor can play as caregiver and navigator by providing physicians with actionable information, tools and value-based payments that reward physicians for improved quality, patient experience and affordability,” said Larry Schreiber, president and CEO, Empire BlueCross BlueShield.

Empire currently participates in the Capital District-Hudson Valley Region Comprehensive Primary Care Initiative (CPCi), a pilot that launched in 2012 and will sunset at the end of 2016. CPC+ represents an opportunity to build on the success of CPCi along with the other value-based, patient-centered care programs that Empire has grown over the last four years under its provider collaboration work, known as Togetherworks.

“Empire has demonstrated our commitment to payment innovation and provider collaboration and transformation,” added Schreiber. “Empire’s selection as a payer participant in CPC+ presents an opportunity to collaborate with CMS, providers and other payers to continue to shift our delivery system to one that rewards quality and value.”

Empire works with nearly 10,200 providers across New York under its own value-based, patient-centered care program. By 2018, Empire and its affiliated health plans in 13 other states aim to have more than half of their combined spending in alternative payment models rather than traditional fee for service arrangements.

Building on the medical home concept, CPC+ intentionally aligns multi-payer payment reform with practice transformation, holding practices accountable for total cost of care and improved quality. Under this initiative, practices will be able to engage in systematic data sharing and collaborative learning experiences and will also have an opportunity to share savings achieved. CMS sought to collaborate with other payers in 20 markets and will work with health information technology vendors to provide products to advanced CPC+ practices.

New York providers who want to participate in CPC+ must apply to CMS and will be announced later this year.

About Empire BlueCross BlueShield

Serving New Yorkers for 80 years, Empire BlueCross BlueShield is the largest health insurer in New York supporting more than four million members and more than 38,000 business, union and small employers in New York. Empire BlueCross BlueShield (Empire) is the trade name of Empire HealthChoice Assurance, Inc., and Empire Blue Cross Blue Shield HMO is the trade name of Empire HealthChoice HMO, Inc., independent licensees of the Blue Cross Blue Shield Association, serving residents and businesses in the 28 eastern and southeastern counties of New York State. Additional information about Empire is available at www.empireblue.com. Also, follow us on Twitter at @empirebcbs.